OClawVPS.com
Vyome Therapeutics, Inc.
Edit

Vyome Therapeutics, Inc.

https://www.vyometx.com/
Last activity: 22.01.2025
Active
Categories: BioTechDataDesignDevelopmentMedtechPlatformProductResearchSmartTechnology
Vyome Therapeutics Inc. is laser-focused on unmet medical needs and addressing them with novel therapeutic products that regulate the immuno-inflammation response. We rely on 3 principles to create impact and value: Focus on unmet medical need: We differentiate from the crowd by truly diving deep into our medical knowledge and expertise to identify significant unmet medical needs that currently have no approved products. We select only those unmet needs that can be clinically addressed and offer a clear regulatory path for development. Create strong mechanistic IP around treating the disease: We leverage a strong mechanistic understanding of the causes and drivers of the disease to identify the best target, the optimal product, and tractable clinical endpoints. A strong mechanistic basis also allows us to create new IP. Vyome has over 75 patents granted or pending. Laser focus on smart clinical trial design and execution: We bring a thoughtful and creative approach to clinical development. We are laser focused on (1) The right patient pool, (2) Identifying endpoints that are meaningful and achievable; and (3) Trial design that enable the generation of registrational data in a cost-effective manner. These 3 principles, interlinked, allow us to maximize impact and value while minimizing risks and costs.
Followers
3.78K
Website visits
1.8K /mo.
Mentions
2
Location: United States, New Jersey, Princeton
Employees: 11-50
Founded date: 2017

Investors 1

Mentions in press and media 2

DateTitleDescription
22.01.2025Vyome Therapeutics Presents Positive Data from Early Analysis of a Phase 2 Study of VT-1953 in Malignant Fungating WoundVT-1953 significantly improves primary end point and quality of life of patients CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day per...
09.01.2025Vyome Therapeutics featured on Yahoo! FinanceVyome highlighted as example of successful collaboration in the US/India innovation ecosystem CAMBRIDGE, MA, UNITED STATES, January 9, 2025 /EINPresswire.com/ -- - To-be listed Vyome Holdings Inc. Chairman and Remus Capital CEO Krishna K. G...

Reviews 0

Sign up to leave a review

Sign up Log In